NASDAQ · PRE
Prenetics Global Limited
$18.98+$0.46 (+2.48%)
Prenetics Global Limited’s quoted price sits in the lower half of its reported 52-week range, 30.32% below the high.
Loading market information…
OTC · BACK · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
IMAC Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
IMAC Holdings, Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$4.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow IMAC Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
IMAC Holdings, Inc. operates a network of advanced medical and regenerative care facilities across the United States. Through its outpatient clinics, the company delivers a range of regenerative, orthopedic, and minimally invasive treatments. These services target individuals suffering from various ailments, including sports-related injuries, damage to ligaments and tendons, other soft tissue issues, and chronic pain in the back, knees, and other joints. Additionally, IMAC offers physical therapy, spinal decompression, and chiropractic manipulation. Currently, IMAC Holdings oversees 15 outpatient medical centers situated in six states: Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. Established in 2000, IMAC Holdings, Inc. maintains its corporate headquarters in Brentwood, Tennessee.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:59 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $15.75K-98.43% vs estimate |
| Q1 2024 | May 15, 2024 | -$0.35+61.54% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q1 2024 | Apr 16, 2024 | -$1.31-79.45% vs estimate | -$5.00M-600.0% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$18.98+$0.46 (+2.48%)
Prenetics Global Limited’s quoted price sits in the lower half of its reported 52-week range, 30.32% below the high.
CA$4.65-CA$0.21 (-4.32%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 74.17% below the high.
$4.20+$0.17 (+4.22%)
P3 Health Partners Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.13% below the high.
₪0.01₪0.00 (0.0%)
Purple Biotech Ltd.’s quoted price sits in the upper half of its reported 52-week range, 41.18% below the high.
$1.97-$0.07 (-3.43%)
Aclarion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.95% below the high.
$0.84-$0.03 (-3.84%)
Dermata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.95% below the high.
$2.91-$0.42 (-12.61%)
NLS Pharmaceutics AG’s quoted price sits in the lower half of its reported 52-week range, 93.29% below the high.
$5.78+$0.12 (+2.12%)
Nuwellis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.63% below the high.
